phage infiltration and tubular damage in an isolated renal perfusion model. How can antibiotics worsen acute kidney injury but improve survival in experimental sepsis?* S epsis and septic shock are the most common causes of morbidity and mortality among critically ill patients and remain the leading causes of acute kidney injury (AKI) among this population (1-3). Sepsis-induced AKI is independently associated with increased mortality and longer hospital stay (2, 4) . AKI severity, as defined by RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) and Acute Kidney Injury Network criteria, parallels with increased hospital mortality in the general intensive care unit population (5) . Despite much recent attention toward the interaction between sepsis and AKI, their relationship is still murky. Do patients die with AKI or of AKI? A seemingly straightforward study reported in this issue of Critical Care Medicine by Peng and colleagues (6) now challenges the way we view sepsis-induced AKI in the intensive care units by showing that a commonly used antibiotic regimen temporarily worsens AKI severity while improving survival in experimental sepsis. This demonstrates a clear dissociation between AKI status and survival, which requires validation and reexamination in other settings, in larger groups. The questions raised in this study could have substantial implications in the way that we view AKI end points, and follow-up studies are needed to examine the unintended effects of antibiotics and underlying mechanisms.
Despite important new insights into the pathophysiology of sepsis, one of the cornerstones of sepsis treatmentthe use of antibiotics together with volume resuscitation (and source control, if possible)-has not changed over the past four decades (7). Effective antibiotic administration within the first hour of documented hypotension is associated with increased survival at hospital discharge in adult patients with septic shock (8) , and delays to appropriate antimicrobial therapy contribute to significant increases in the incidence of septic AKI (9) . In a more contemporary cohort of patients with septic shock, AKI development was independently associated with delay to initiation of adequate antibiotics (10) .
The use of animal models to study sepsis requires balancing clinical relevance vs. simplicity (easier to interpret) and practicality (easier to do). Although use of antibiotics and fluid resuscitation is now standard practice in animal models, there is substantial variance between laboratories, probably as a result of differing adaptations of clinically relevant regimens. Peng et al administered antibiotics 18 hrs after cecal ligation and puncture in rats, which is substantially later than the 6-hr time point when we and others have initiated antibiotics. As expected, Peng and colleagues found that antibiotics improved survival but paradoxically increased AKI at nonnephrotoxic doses.
How could this happen? One avenue explored by Peng et al is that within the context of sepsis, antibiotics increase AKI and inflammation along a liver damage and interleukin-6 axis. Do antibiotics improve survival because of AKI (and/or inflammation) or despite it? This dichotomy may depend on the dose, timing, and/or type of antibiotic administered. The authors raise the possibility that bactericidal antibiotics may release endotoxin (lipopolysaccharide) from bacteria, thus inducing inflammation (11) . Lipopolysaccharide and other bacterial constituents could activate Toll-like receptors and subsequent MyD88-dependent activation of the transcription factor nuclear factor-B and production of cytokines. If inflammation is beneficial, then a proinflammatory cytokine such as tumor necrosis factor-␣ (12) could enhance the survival benefit from antibiotics. Conversely, an interleukin-6-based adjunctive anti-inflammatory therapy (13) could improve survival if antibioticinduced inflammation was an unavoidable side effect of the bactericidal antibiotics. Of note, neither of these studies (12, 13) used antibiotics, and therefore the effects of these treatments could be different within the context of antibiotic treatment.
Peng and colleagues point out an intriguing possibility from their data that antibiotic-treated cecal ligation and puncture sepsis survivors recover from AKI and inflammation faster. Does the inflammation accelerate resolution of the infection? It probably depends on the context. Therefore, the clinical relevance of these findings will depend on the universality of the observations by Peng and colleagues. Do antibiotics increase AKI and inflammation while improving survival in other sepsis models such as pneumonia? Similarly, if these phenomena are observed in older animals with sepsis, or those with preexisting comorbidities such as chronic kidney disease (14) , these observations should have more direct translation to the aging patient population with sepsis.
What if resolution of AKI (15) is indeed more tightly associated with survival than onset or peak of AKI is associated with mortality? The authors astutely point out that AKI biomarkers may not be adequate intermediate end points to develop therapeutic strategies for patient with sepsis-AKI. In other words, AKI may not always be on the causal pathway to sepsis-induced mortality; therefore, we may need biomarkers that distinguish lethal from "nonlethal/beneficial" AKI.
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